Latest Breaking News On - Upcoming scientific - Page 1 : comparemela.com

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkJoe oconnorYuko yoneyamaChris stammBarbara shecterGabriel friedmanExchange commissionUpcoming scientific congressBell canadaInternational mediaTakeda pharmaceutical company limitedNational postBusiness wireRapidly initiateFirst global phase

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

United statesYuko yoneyamaTakeda pharmaceutical company limitedExchange commissionUpcoming scientific congressKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testAnnual reportMedia contactTakeda tak861 orexin receptor 2 ox2r narcolepsy type 1 nct05687903 nct05687916 nt1 nt2 maintenance of wakefulness test epworth sleepiness scale weekly cataplexy rate sarah sheikh gastrointestinal inflammation rare diseases plasmaderived therapies oncology neuroscience vaccines

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonis

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass. (BUSINESS WIRE) Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu.

United statesYuko yoneyamaUpcoming scientific congressTakeda pharmaceutical company limitedExchange commissionKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testAnnual report

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSarah sheikhYuko yoneyamaExchange commissionInternational mediaGlobal development at takedaTakeda pharmaceutical company limitedUpcoming scientific congressKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testNeuroscience therapeutic area unitGlobal development

Nicox to Present at Upcoming Scientific Conferences

Press ReleaseNicox to Present at Upcoming Scientific ConferencesMarch 3, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris:.

New yorkUnited statesProvence alpes côd azurFrance generalUnited kingdomCity ofEric yooGavin spencerYi chenPharma bioStates mont blancArsene guekamPooya hemamiMont blancSophia antipolisKepler cheuvreux